SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR DAPAGLIFLOZIN REDUCES SYSTEMIC H-FABP AND MONOCYTE-TO-LYMPHOCYTE RATIO IN PRECLINICAL MODELS OF ANTRACYCLINE INDUCED CARDIOTOXICITY
Nicola MaureaMartina IovineAlessia MerolaVienna GiordanoAndrea PacconeFrancesca BruzzeseGiuseppe PalmaAntonio LucianoIlaria GiacobbeIrma BiscegliaVincenzo Quagliariello
0
Citation
0
Reference
10
Related Paper
Keywords:
Dapagliflozin
Cardiotoxicity
Monocyte
Cardiotoxicity
Cite
Citations (20)
Objective: Various methods are used to determine a person’s opioid/marijuana status. However, more specific and sensitive markers are needed that are easily applicable and accessible. Complete blood count (CBC) is a convenient method to be used for this purpose. In this study, we investigated the relationship between CBC values – particularly monocyte-to-lymphocyte ratio (MLR) and platelet-to-lymphocyte ratio (PLR) – and opioid/marijuana use disorder. Method: We compared CBC values of 56 male patients diagnosed with opioid use disorder (OUD), 56 male patients diagnosed with marijuana use disorder (MUD), and 56 healthy subjects. Results: The percentage of monocytes was significantly higher in the MUD group compared to the OUD group (p=0.010). The monocyte count was significantly different in the MUD group compared to the other two groups (p=0.018). MLR was significantly higher in the MUD group than in the OUD group (p=0.049). PLR was significantly different from the other two groups in the OUD group (p=0.038). In the MUD group, percentage of monocytes was declining with age (r=-0.474, p=0.011). The area under the receiver operating characteristic curve of the monocyte count value for MUD was 0.670. Conclusion: Measurements like lymphocyte- and monocyte-related ratios in OUD and MUD can be important in monitoring and detecting the substance and for differentiating between acute and chronic conditions. In order to clarify the subject, further studies with fewer limitations are needed.
Monocyte
Cite
Citations (6)
This study was designed to compare the complete blood count values of opioid users (N = 61) and healthy subjects (N = 61), particularly monocyte-to-lymphocyte ratio (MLR) and platelet-to-lymphocyte ratio (PLR). PLR, MLR, and percentage of monocyte (MONO%) were significantly lower in opioid use disorder (OUD) group (P = 0.012, P = 0.005, P = 0.000). The area under the ROC curve of MLR and PLR levels for OUD was 0.349 and 0.368. MONO% correlated with substance use duration. Measurements like lymphocyte-related ratios and MONO% in opioid use can be important in substance monitoring, detection, and differentiation of acute and chronic conditions.
Monocyte
Cite
Citations (45)
ObjectivesDapagliflozin is an inhibitor of the human sodium-glucose co-transporter 2 (SGLT2) that has been shown to improve glycaemic control in patients with type 2 diabetes mellitus (T2DM). This study aimed to evaluate the characteristics and treatment patterns of dapagliflozin users in comparison to users of other anti-diabetic (AD) treatments in Germany.MethodsData from patients with T2DM initiating at least one prescription for dapagliflozin or other AD therapy between November 2012 and April 2014 were collected from the IMS German Disease Analyzer database.ResultsThe use of dapagliflozin combination therapy (n = 1034; 74%) was more common than monotherapy (n = 371; 26%). In comparison with other AD therapy users, a higher percentage of dapagliflozin users were ⩽64 years of age (62.3% vs. 36.4%), and a higher proportion were male (59.1% vs. 53.6%). The average duration of diabetes was comparable between dapagliflozin patients and other AD therapy users (5.7 years vs. 5.5 years), however higher levels of HbA1c were found in dapagliflozin users (8.2% (66 mmol/mol) vs. 7.5% (58 mmol/mol). For the vast majority (71.5% of 10 mg dapagliflozin users and 88.9% of 5 mg users), dapagliflozin was prescribed in combination with other AD therapy.ConclusionsPatients starting on dapagliflozin differed in several demographic and health-related respects to patients starting another AD therapy during the same period. Dapagliflozin was predominantly used as a component of combination therapy, adding on to existing therapy. After initiation, switching to other AD treatments or adding to therapy was comparatively rare during the first year.
Dapagliflozin
Combination therapy
Cite
Citations (4)
Monocyte
Cite
Citations (0)
Objective: This study aims to investigate the level of peripheral blood mononuclear cells and their ratios which may point to the immunological mechanisms involved in the etiopathogenesis of ASD.Method: The complete blood count parameters of the 45 ASD cases were compared with those of healthy controls.Childhood Autism Rating Scale (CARS) was performed to measure the disease severity.Results: The monocytes of ASD group were significantly higher; and the lymphocyte-to-monocyte ratio (LMR) was lower than the controls'. LMR and neutrophil-to-lymphocyte ratio were found to be predictors of ASD. The decrease in LMR (B: −0.744; P=0.035; CI: −1.431 to −0.056) and the increase in age (B: 0.432; P=0.045; CI: 0.011–0.853) were related to high CARS scores in linear regression analyses.Conclusions: The results of this study support the role of altered immune cell counts and ratios in ASD. A high monocyte level and low LMR may have diagnostic values in autism.
Monocyte
Cite
Citations (33)
배경: 인듐은 휴대전화, TV를 비롯한 디지털기기에서 디스플레이패널의 핵심소재로 사용되는 금속이다. 과거 인듐은 인체에 무해한 금속으로 여겨졌으나 인듐노출로 인한 폐질환자와 사망자 발생을 계기로 일부 국가에서 그 유해성에 대한 연구가 진행되고 있다. 우리나라는 디스플레이 패널 세계시장점유율 1위로 세계 디스플레이 패널의 약 50%를 공급하고 있는 세계 제1의 인듐 소비 국가이다. 하지만 인듐 노출에 의한 건강영향 연구는 미비한 상황이며 폐질환 예방체계 및 검진기준 또한 마련되지 못한 실정이다. 따라서 본 연구를 통해 국내 인듐취급 근로자를 대상으로 백혈구 수치 변화를 확인하고 검진기준 마련을 위한 기초자료를 제공하고자 하였다. 방법: 국내에서 인듐을 취급하는 디스플레이 제조 관련 공장의 남성근로자 156명을 대상으로 하였다. 혈청 인듐은 ICP-MS (bruker), KL-6는 ELISA (EIDIA), 백혈구 분별계수는 자동혈구계수기(sysmex XE-2100)를 이용하여 분석하였다. 자료분석은 version18.0 SPSS Statistics 프로그램을 이용하였고 통계적 유의수준은 p＜0.05로 하였다. 결과: 혈청인듐의 일본참고치 3 μg/L 초과자에서 neutrophil, lymphocyte, monocyte, eosinophil이 의미있는 변화를 보였으며 인듐농도의 증가에 따라 neutrophil의 증가경향과 lymphocyte의 감소경향이 뚜렷하였다(p for trend＜0.05). KL-6의 일본참고치 500 U/mL 초과자에서는 neutrophil, lymphocyte, monocyte의 변화가 의미 있었으며 KL-6의 농도 증가에 따라 neutrophil은 증가하였으나, lymphocyte, monocyte, eosinophil은 뚜렷한 감소경향을 보였다(p for trend＜0.05). 혈청 인듐 또는 KL-6를 독립변수로, 백혈구 분별계수 결과 및 백분율을 독립변수로 회귀분석을 실시한 결과 혈청인듐은 영향력이 낮았으나 KL-6는 neutrophil의 증가와 lymphocyte, monocyte의 감소에 영향을 주는 것으로 분석되었다. 결론: 백혈구 총 수치와 분별계수결과는 모두 정상범위이나 일본의 참고치를 초과한 그룹에서 neutrophils의 증가, lymphocyte와 monocyte의 의미 있는 감소가 확인되었다. 이는 연구대상자에서 neutrophil을 증가시킬 수 있는 감염, 스테로이드 약물치료 등이 없었으며 혈청 인듐 농도 및 간질성폐질환의 마커인 KL-6의 농도 변화에 따라 의미 있는 변화를 보였으므로 직업적 인듐노출로 인한 백혈구 수치의 변화라고 판단된다. 고농도의 인듐노출에서도 변화의 폭이 작아 진단지표로 활용가치는 낮으나 특발성폐섬유증, 폐석면증 등의 질환에서 neutrophil이 증가하였다는 보고가 있으므로 인듐에 의한 간질성 폐질환예방을 염두에 둔 진단항목 개발과 인듐에 의한 폐질환발생기전 파악 등의 후속연구 진행이 요구된다.
Monocyte
Cite
Citations (0)
The effect of sera from patients with Hodgkin's disease (HD) on monocyte dependent ConA and MLC-activation of normal lymphocytes to DNA synthesis was studied. Lymphocyte stimulation was greatly enhanced in the presence of monocytes at a monocyte : lymphocyte ratio of less than or equal to 8 : 1. Higher ratios were usually suppressive. Some HD sera suppressed monocyte mediated enhancement of ConA and MLC-stimulation efficiently. The degree of inhibition by the individual HD serum remained similar in the absence of monocytes and at various monocyte : lymphocyte ratios. Pretreatment of monocytes or lymphocytes with HD serum had no effect. Inhibition was only noted when serum was present during the whole culture period. It is concluded that HD sera do not hamper the activity of monocytes to augment lymphocyte growth. The effect may be explained by direct effects of serum factors on lymphocytes.
Monocyte
Cite
Citations (1)
OBJECTIVE To describe the efficacy and safety of dapagliflozin, the first sodium-glucose co-transporter-2 (SGLT-2) inhibitor for the treatment of diabetes mellitus type 2 (DM2) to be registered in the Netherlands. DESIGN Literature review. METHOD We searched the Medline database for articles on the use of dapagliflozin in patients with DM2. We included randomised studies with a minimum duration of 12 weeks and systematic reviews published up to 19 October 2012. Two assessors selected the articles on the basis of title, abstract and if necessary, the complete text. RESULTS Eleven articles were suitable for analysis. On comparison with placebo, the use of dapagliflozin gave a drop in HbA1c-value of approximately 0.5-0.8 percentage points (6-9 mmol/mol). The body weight of patients who used dapagliflozin dropped between 1.0-2.4 kg on comparison with the placebo and metformin control groups. Urinary tract infections occurred twice as often and genital infections three to four times more often. There were no data on the effect on micro- and macrovascular complications or on mortality. CONCLUSION Dapagliflozin regulates the blood glucose levels less effectively than currently used medications, although the small number of studies that compare dapagliflozin with metformin or glipizide show no differences in the drop in HbA1c between the study groups. Dapagliflozin use leads to minor, clinically non-relevant weight loss. There are as yet no data on its long term efficacy and safety.
Dapagliflozin
Glycosuria
Canagliflozin
Glipizide
Empagliflozin
Cite
Citations (1)
Dapagliflozin is an oral agent for type 2 diabetes mellitus (T2DM) belonging to the sodium/glucose cotransporter 2 inhibitor (SGLT2-I) class of antihyperglycemic medications. In clinical trials, dapagliflozin has also been shown to reduce cardiovascular and major renal events. In the DAPA-CKD trial, dapagliflozin significantly reduced the composite renal outcome in patients with chronic kidney disease (CKD). Dapagliflozin represents a new pharmacologic option for reducing CKD progression in patients with and without diabetes.
Dapagliflozin
Cite
Citations (1)